The role of Irbesartan in the treatment of patients with hypertension: A comprehensive and practical review

High Blood Pressure and Cardiovascular Prevention

Volumn 19, Issue 1, 2012, Pages 19-31

  Borghi, Claudio ^a   Cicero, Arrigo F G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

AT1 receptor antagonists; Hypertension; Irbesartan; Organ damage

Indexed keywords

ADIPONECTIN; ALBUMIN; AMIODARONE; AMLODIPINE; ATENOLOL; C REACTIVE PROTEIN; CANDESARTAN; CREATININE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLUCOSE; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; THIOCTIC ACID; TRIACYLGLYCEROL; VALSARTAN;

ABDOMINAL OBESITY; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; COST CONTROL; COUGHING; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSLIPIDEMIA; DYSPEPSIA; FATIGUE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; ITALY; LIFE EXPECTANCY; LIVER METABOLISM; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; COMORBIDITY; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 84861929378     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11632100-000000000-00000     Document Type: Review

References (77)

1. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 1999; 39: 547-59 (Pubitemid 30629034)
2. RuilopeL.Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. J Hypertens 1997; 15 Suppl. 7: s15-20 (Pubitemid 28069990)
3. Bristol Myers Squibb Company. Avapro (irbesartan) United States prescribing information. Princeton (NJ): Bristol Myers Squibb Company. Last text revision: 2005 Oct [online]. Available from URL: http://www.bms.com [Accessed 2006 Mar 31]
4. Physicians Desk Reference Electronic Library website. Last text revision: 2005 Jul [online]. Available from URL: http://www.micromedex.com/products/ pdrlibrary [Accessed 2006 Mar 6]
5. Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998; 26 (5): 408-17 (Pubitemid 28223881)
6. Vachharajani NN, Shyu WC, Mantha S, et al. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol 1998; 38 (5): 433-6 (Pubitemid 28224216)
7. Croom KF, Curran MP, Goa KL, et al. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64: 999-1028 (Pubitemid 38608479)
8. Vachharajani NN, Shyu WC, Chando TJ, et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol 1998; 38 (8): 702-7 (Pubitemid 28388219)
9. Markham A, Spencer C. Irbesartan: an updated review of its use in cardiovascular disorders. Drugs 2000; 59 (5): 1187-206 (Pubitemid 30339143)
10. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33 (6): 1406-13 (Pubitemid 29282662)
11. Official drug review [online]. Available from URL: http://www. torrinomedica.it/farmaci/schedetecniche/Aprovel-300-Mg.asp [Accessed 2011 Jun]
12. Marino MR, Langenbacher K, Ford NF, et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38: 246-55 (Pubitemid 28144930)
13. Sica DA, MarinoMR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure andmaintenance hemodialysis. Clin Pharmacol Ther 1997; 62: 610-8 (Pubitemid 28068064)
14. Marino MR, Marino MR, Hammett JL, et al. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998; 38: 347-56 (Pubitemid 28194175)
15. Bramlage P, Durand-Zaleski I, Desai N, et al. The value of irbesartan in the management of hypertension.ExpertOpin Pharmacother 2009; 10 (11): 1817-31
16. Borghi C, Ertek S, Cicero AFG. Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. Future Drugs 2006; 3 (69): 733-49 (Pubitemid 44890521)
17. Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511-8 (Pubitemid 28039581)
18. Pool JL, Guthrie RM, Littlejohn 3rd TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-70 (Pubitemid 28231459)
19. Guthrie R, Saini R, Herman T, et al. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: a double-blind, placebo-controlled, dose-titration study. Clin Drug Invest 1998; 15: 217-27 (Pubitemid 28163748)
20. Reeves RA, Lin CS, Kassler-Taub K, et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998; 31: 1311-6 (Pubitemid 28248833)
21. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-tomoderate hypertension. Am J Hypertens 1998; 11: 445-53 (Pubitemid 28231457)
22. Oparil S, Guthrie R, Lewin AJ, et al. An elective titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan. Clin Ther 1998; 20: 398-409 (Pubitemid 28343494)
23. Mancia G, Korlipara K, van Rossum P, et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 1-8
24. Bobrie G, Delonca J, Moulin C, et al. on behalf of the COmparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension(COSIMA) Investigators. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18 (11): 1482-8
25. Lewis EJ, Hunsicker LG, Clarke WR, et al., on behalf of the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
26. Brenner BM, Cooper ME, de Zeeuw D, et al., on behalf of the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001; 345 (12): 861-9
27. Berl T, Hunsicker LG, Lewis JB, et al., on behalf of the Irbesartan Diabetic Nephropathy Trial, Collaborative Study Group. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542-9
28. Parving HH, Lehnert H, Bröchner-Mortensen J, et al., on behalf of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8
29. Andersen S, Bröchner-Mortensen J, Parving HH, on behalf of the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003; 26: 3296-302 (Pubitemid 37466890)
30. Viberti G, Wheeldon NM, on behalf of the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressureindependent effect. Circulation 2002; 106: 672-8 (Pubitemid 34851925)
31. Haller H, Ito S, Izzo Jr JL, et al., on behalf of the ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011 Mar 10; 364 (10): 907-17
32. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: 11-20
33. Ghosh A. The metabolic syndrome: a definition dilemma. Cardiovasc J Africa 2011; 22 (6): 296-7. 2
34. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP): expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2479-86
35. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (executive summary). Circulation 2005; 112: e285-90
36. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9 (Pubitemid 36935533)
37. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9 (Pubitemid 32893993)
38. Mancia G, De Backer G, Dominiczak A, et al., Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87
39. Mancia G, Laurent S, Agabiti-Rosei E, et al., on behalf of the European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58
40. Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation. Hypertension 2008; 52: 1030-7
41. Dronavalli S, Bakris GL. Mechanistic insights into diuretic-induced insulin resistance. Hypertension 2008; 52: 1009-11
42. Israili ZH, Lyoussi B, Hernandez-Hernandez R, et al. Metabolic syndrome: treatment of hypertensive patients. Am J Ther 2007; 14: 386-402 (Pubitemid 47224822)
43. Sowers JR, Neutel JM, Saunders E, et al. Antihypertensive efficacy of irbesartan/ HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens 2006; 8: 470-80
44. ParhoferKG, Münzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. Cardiovasc Diabetol 2007; 6: 36
45. Baumhäkel M, Schlimmer N, Böhm M, on behalf of the DO-IT Investigators. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008; 20 (5): 493-500
46. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7 (Pubitemid 46111014)
47. Bakris GL, Stockert J, Molitch M, et al., on behalf of the STAR Investigators. Risk factor assessment for new onset diabetes: literature review. Diab Obes Metab 2009; 11: 177-87
48. McMurray JJ, Holman RR, Haffner SM, et al., on behalf of theNAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362 (16): 1477-90
49. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105
50. Kintscher U, Foryst-Ludwig A, Unger T. Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin Ther Targets 2008; 12: 1257-63
51. Takai S, Jin D, Miyazaki MJ. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor g. Pharmacol Sci 2011; 116 (3): 309-15
52. Kintscher U, Bramlage P, Paar WD, et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey - prospective observational, two armed study in 14, 200 patients. Cardiovasc Diabetol 2007; 6: 12
53. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005 Jan 25; 111 (3): 343-8 (Pubitemid 40165342)
54. Parhofer KG, Birkeland KI, DeFronzo R, et al. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). Int J Clin Pract 2010 Jan; 64 (2): 160-8
55. Russell JC, Kelly SE, Vine DF, et al. Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR : LA-cp rats. Br J Pharmacol 2009; 158 (6): 1588-96
56. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19 (6): 1167-76 (Pubitemid 32493652)
57. Gaudio C, Ferri FM, Giovannini M, et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003; 42: 622-8 (Pubitemid 37305980)
58. Mörtsell D, Malmqvist K, Held C, et al. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med 2007 May; 261 (5): 472-9 (Pubitemid 46587719)
59. Yusuf S, Healey JS, Pogue J, et al., on behalf of the ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364 (10): 928-38
60. Lindenfeld J. Does irbesartan improve the risk of death or hospitalization for cardiovascular causes among patients with HF and PEF? Curr Cardiol Rep 2010;12 (3): 193-5
61. Massie BM, Carson PE, McMurray JJ, et al. on behalf of the i-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359 (23): 2456-67
62. Yusuf S, Pfeffer MA, Swedberg K, et al., on behalf of the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMpreserved Trial. Lancet. 2003; 362: 777-81 (Pubitemid 37093918)
63. Cleland JG, Tendera M, Adamus J, et al., on behalf of the PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-45
64. Solomon SD, Janardhanan R, Verma A, et al., on behalf of the Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007; 369 (9579): 2079-87 (Pubitemid 46935945)
65. Dilaveris P, Giannopoulos G, Synetos A, et al. The role of renin angiotensin system blockade in the treatment of atrial fibrillation. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 387-403 (Pubitemid 41637624)
66. Schneider MP, Hua TA, Böhm M, et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010 May 25; 55 (21): 2299-307
67. Zaman AG, Kearney MT, Schecter C, et al. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004; 147: 823-7 (Pubitemid 38880988)
68. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long lasting FA: a randomized prospective study. Circulation 2002; 106: 331-6 (Pubitemid 34778957)
69. Madrid AH, Marín IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation: the dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114-20 (Pubitemid 39406720)
70. Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long- Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48 (3): 385-91 (Pubitemid 44253730)
71. Ducharme A, Swedberg K, Pfeffer MA, et al., on behalf of the CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152 (1): 86-92
72. Disertori M, Latini R, Barlera S, et al., on behalf of the GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360 (16): 1606-17
73. Simon TA, Gelarden RT, Freitag SA, et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998; 82 (2): 179-82 (Pubitemid 28337728)
74. Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of irbesartan in hypertensive type 2 diabetics with nephropathy: an Italian perspective [in Italian]. Pharmacoecon Ital Res Articles 2005; 7 (1): 43-57 (Pubitemid 40347326)
75. Ravera M, Ratto E, Vettoretti S, et al. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol 2005; 16: s48-52 (Pubitemid 41725083)
76. American Diabetes Association. Position statement: diabetic nephropathy. Diabetes Care 2003; 26 Suppl. 1: s94-8
77. American Diabetes Association. Position statement: standards of medical care in diabetes. Diabetes Care 2009; 32 Suppl. 1: S1-61